Myrna Candelaria

7PUBLICATIONS
24CO-AUTHORS
Predictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)Epidemiology not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 14, 2024
Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients.

Myrna Candelaria, Dennis Cerrato-Izaguirre, Olga Gutierrez

|Oct 14, 2022
ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma.

José Díaz-Chávez, Olga Gutiérrez-Hernández, Lucia Taja-Chayeb

|Jul 16, 2021
Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos.

Luis Malpica, Daniel J Enriquez, Denisse A Castro

|Apr 02, 2021
Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma.

Myrna Candelaria, Alfonso Dueñas-Gonzalez

|Jul 06, 2019
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.

Myrna Candelaria, Derlis E González, Marcia Torresan Delamain

|Aug 24, 2017
Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).

Myrna Candelaria, Sebastian Burgos, Mayra Ponce

Pageof 2

Frequent Collaborators

1 joint publications

Luis Malpica

1 joint publications

Daniel J Enriquez

1 joint publications

Denisse A Castro

1 joint publications

Camila Peña